H.C. Wainwright lowered the firm’s price target on Savara (SVRA) to $6 from $10 and keeps a Buy rating on the shares. The firm questions if Savara will be able to reach its goal of identifying 1,000 patients by the Molbreevi launch.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA: